Julian S. Gangolli's Insider Trades & SAST Disclosures
Julian S. Gangolli's most recent trade in Outlook Therapeutics Inc was a trade of 71,169 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Julian S. Gangolli.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 71,169 | 71,169 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 56,636 | 56,636 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.75 per share. | 20 May 2024 | 20,000 | 20,000 (0%) | 0% | 22.8 | 455,000 | Common Stock |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Sale of securities on an exchange or to another person at price $ 163.71 per share. | 20 May 2024 | 10,930 | 9,070 (0%) | 0% | 163.7 | 1,789,310 | Common Stock |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Sale of securities on an exchange or to another person at price $ 164.34 per share. | 20 May 2024 | 7,090 | 1,980 (0%) | 0% | 164.3 | 1,165,180 | Common Stock |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Sale of securities on an exchange or to another person at price $ 165.76 per share. | 20 May 2024 | 1,980 | 0 (0%) | 0% | 165.8 | 328,200 | Common Stock |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 23,458 | 23,458 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 15,000 | 45,106 (0%) | 0% | 0 | Common Stock | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 94,441 | 94,441 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 5,915 | 5,915 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 3,534 | 30,106 (0%) | 0% | 0 | Common Stock | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 41,065 | 41,065 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 74,398 | 74,398 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 10,756 | 10,756 | - | - | Stock Option (Right to buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 21,878 | 21,878 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 44,466 | 44,466 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 7,551 | 7,551 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 4,013 | 20,513 (0%) | 0% | 0 | Common Stock | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 20,873 | 20,873 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2020 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 35,006 | 35,006 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Julian S. Gangolli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges